Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Profit After Tax (2022 - 2025)

Taysha Gene Therapies' Profit After Tax history spans 4 years, with the latest figure at -$32.7 million for Q3 2025.

  • For Q3 2025, Profit After Tax fell 28.24% year-over-year to -$32.7 million; the TTM value through Sep 2025 reached -$99.9 million, down 338.82%, while the annual FY2024 figure was -$89.3 million, 19.96% up from the prior year.
  • Profit After Tax for Q3 2025 was -$32.7 million at Taysha Gene Therapies, down from -$26.9 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $47.7 million in Q4 2023 and bottomed at -$117.1 million in Q3 2023.
  • The 4-year median for Profit After Tax is -$25.5 million (2024), against an average of -$29.9 million.
  • The largest YoY upside for Profit After Tax was 186.68% in 2023 against a maximum downside of 341.39% in 2023.
  • A 4-year view of Profit After Tax shows it stood at -$55.1 million in 2022, then soared by 186.68% to $47.7 million in 2023, then crashed by 139.35% to -$18.8 million in 2024, then plummeted by 74.25% to -$32.7 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Profit After Tax are -$32.7 million (Q3 2025), -$26.9 million (Q2 2025), and -$21.5 million (Q1 2025).